HPTN 108/ PAUSE STUDY
HPTN 108 Study: Pausing Antiretroviral Treatment Under Structured Evaluation (PAUSE Study). The HPTN 108 Study, also known as the PAUSE Study, is a Phase 1, randomized, placebo-controlled trial investigating the safety, efficacy and tolerability of the combination of two long-acting broadly neutralizing antibodies (bNAbs), 3BNC117-LS-J and 10-1074-LS-J, in ART-treated adults living with HIV in sub-Saharan Africa. The study focuses on whether these bNAbs, administered through intravenous infusion, will be safe, well-tolerated, and capable of maintaining durable viral suppression in the absence of antiretroviral therapy (ART) during a monitored analytical treatment interruption (ATI).
Study Objectives
The primary objective of this study is to determine whether the combination of 3BNC117-LS-J and 10-1074-LS-J can effectively maintain viral suppression in people living with HIV while pausingĀ ART, provided the bNAbs remain at therapeutic levels. The study will assess both the safety and efficacy of this innovative treatment strategy, which could represent a significant advancement in HIV management if proven effective.
Investigators
- Prof Sinead Delany-Moretlwe
- Dr Carrie Matthew
Latest Update
August 2024
For more details about HPTN 108 Study please email rhicomms@wrhi.ac.za